Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài:Vorinostat in solid and hematologic malignancies | Journal of Hematology Oncology BioMed Central Open Access Vorinostat in solid and hematologic malignancies David Siegel 1 Mohamad Hussein2 Chandra Belani3 Francisco Robert4 Evanthia Galanis5 Victoria M Richon6 José Garcia-Vargas6 Cesar Sanz-Rodriguez7 and Syed Rizvi6 Address Hackensack University Medical Center Hackensack NJ USA 2H. Lee Moffitt Cancer Center Tampa FL USA 3Penn State Cancer Institute Hershey PA USA 4University of Alabama Birmingham AL USA 5Mayo Clinic College of Medicine Rochester MN USA 6Merck Research Laboratories Upper Gwynedd PA USA and 7Merck Research Laboratories Madrid Spain Email David Siegel - dsiegel@ Mohamad Hussein - mhussein@ Chandra Belani - cbelani@ Francisco Robert - pacorobertuab@ Evanthia Galanis - Victoria M Richon - vrichon@ José Garcia-Vargas - jose_garcia-vargas@ Cesar Sanz-Rodriguez - cesar_sanzrodriguez@ Syed Rizvi - syed_rizvi@ Corresponding author Published 27 July 2009 Received 29 May 2009 Journal of Hematology Oncology 2009 2 31 doi 1756-8722-2-31 Accepted 27 July 2009 This article is available from http content 2 1 31 2009 Siegel et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Vorinostat Zolinza a histone deacetylase inhibitor was approved by the US Food and Drug Administration in October 2006 for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma who have progressive persistent or recurrent disease on or following two systemic therapies. This review summarizes evidence on the use of vorinostat in solid and hematologic malignancies and collated tolerability data from the vorinostat clinical trial .
